Dr. Tao, Mi-Hua
Research Fellow
- 02-2789-9151 (L) (Lab) (Room No: N229)
- 02-2652-3078 (O) (Office)
- 02-2782-9142 (Fax)
-
Specialty:
- Viral and Cancer Immunology
- Viral and Cancer Immunotherapy
- Vaccine Development
- Gene Therapy
Education and Positions:
Ph.D. Columbia University (Microbiology and Immunology).
Postdoctoral Fellow. Stanford University (Oncology)
Immunological tolerance is a common feature of chronic viral infections and malignant diseases. The research focus of my laboratory is to understand immunosuppressive mechanisms present in chronic hepatitis B (HBV) infections and in tumor microenvironment, and to develop novel therapeutic strategies to overcome immunosuppression and reactivate virus- and tumor-specific immunity for cure of chronic HBV and HBV-associated hepatocellular carcinoma and other cancers. For HBV studies, we have developed several HBV animal models, including HBV transgenic mice, human liver mice and human immune system mice (generated, respectively, by transplantation of human hepatocytes and/or human hematopoietic stem cells), and HBV pseudoviruses. For cancer immunotherapies, we have developed orthotopic liver cancer model, liver metastasis model of colon cancer, and oncogene-driven spontaneous breast cancer model to evaluate the therapeutic efficacy. Since outbreak of COVID-19 pandemic, we are actively engaged in developing COVID-19 vaccines (mRNA and recombinant RBD) and has transfered the technology to industry. We also developed COVID-19 animal models to help researhers and biotech companies to evaluate efficacy of their drugs, antibodies or vaccines against SARS-CoV-2 infection.
Our Team
- Huang HC, Wang SH, Fang GC, Chou WC, Liao CC, Sun CP, Jan JT, Ma HH, Ko HY, Ko YA, Chiang MT, Liang JJ, Kuo CT, Lee TA, Morales-Scheihing D, Shen CY, Chen SY, McCullough LD, Cui L, Wernig G, Tao MH, Lin YL, Chang YM, Wang SP, Lai YJ, Li CW Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. Journal of medical virology Online ahead of print, Online ahead of print (2023) [JCR] [WOS]
- Kumari Monika, Lu Ruei-Min, Li Mu-Chun, Huang Jhih-Liang, Hsu Fu-Fei, Ko Shih-Han, Ke Feng-Yi, Su Shih-Chieh, Liang Kang-Hao, Yuan Joyce Pei-Yi, Chiang Hsiao-Ling, Sun Cheng-Pu, Lee I.-Jung, Li Wen-Shan, Hsieh Hsing-Pang, Tao Mi-Hua, Wu Han-Chung A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies Journal of Biomedical Science 29(1), 68 (2022-9-12) [JCR] [WOS]
- Lee IJ, Sun CP, Wu PY, Lan YH, Wang IH, Liu WC, Yuan JP, Chang YW, Tseng SC, Tsung SI, Chou YC, Kumari M, Lin YS, Chen HF, Chen TY, Lin CC, Chiu CW, Hsieh CH, Chuang CY, Cheng CM, Lin HT, Chen WY, Hsu FF, Hong MH, Liao CC, Chang CS, Liang JJ, Ma HH, Chiang MT, Liao HN, Ko HY, Chen LY, Ko YA, Yu PY, Yang TJ, Chiang PC, Hsu ST, Lin YL, Lee CC, Wu HC, Tao MH A booster dose of Delta x Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. Journal of Biomedical Science 29(1), 49 (2022) [JCR] [WOS]
- Jung Lee I, Lan YH, Wu PY, Wu YW, Chen YH, Tseng SC, Kuo TJ, Sun CP, Jan JT, Ma HH, Liao CC, Liang JJ, Ko HY, Chang CS, Liu WC, Ko YA, Chen YH, Sie ZL, Tsung SI, Lin YL, Hsuan Wang I, Tao MH A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. Emerging Microbes & Infections 1-45, 1-45 (2022) [JCR] [WOS]
- Hsu FF, Liang KH, Kumari M, Chen WY, Lin HT, Cheng CM, Tao MH, Wu HC An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. International Journal of Pharmaceutics 627, 122256 (2022) [JCR] [WOS]
- Sung PS, Yang SP, Peng YC, Sun CP, Tao MH, Hsieh SL CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation. Journal of Biomedical Science 29(1), 52 (2022) [JCR] [WOS]
- Liang Kang-Hao, Chiang Pao-Yin, Ko Shih-Han, Chou Yu-Chi, Lu Ruei-Min, Lin Hsiu-Ting, Chen Wan-Yu, Lin Yi-Ling, Tao Mi-Hua, Jan Jia-Tsrong, Wu Han-Chung Antibody cocktail effective against variants of SARS-CoV-2 Journal of Biomedical Science 28(1), 80 (2021-11-23) [JCR] [WOS]
- Liang YJ, Teng W, Chen CL, Sun CP, Teng RD, Huang YH, Liang KH, Chen YW, Lin CC, Su CW, Tao MH, Wu JC Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development. HEPATOLOGY (2021) [JCR] [WOS]
- Lien CE, Lin YJ, Chen C, Lian WC, Kuo TY, Campbell JD, Traquina P, Lin MY, Liu LT, Chuang YS, Ko HY, Liao CC, Chen YH, Jan JT, Ma HH, Sun CP, Lin YS, Wu PY, Wang YC, Tao MH*, Lin YL* CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. Scientific Reports 11(1), 8761 (2021) [JCR] [WOS]
- Su SH, Yang TJ, Yu PY, Kang-Hao Liang KH, Chen WY, Yang CW, Wang MJ, Lin HT, Lu RM, Tso HC, Chung MJ, Hsieh TY, Chang YL, Lin SC, Fang-Yu Hsu FY, Ke FY, Wu YH, Hwang YC, Liang JJ, Liao CC, Sun CP, Wu PY, Lin YL*, Tao MH*, Liao JC*, Hsu STD*, Wu HC* Potent neutralizing antibody cocktail for prevention and treatment of COVID-19 PLOS PATHOGENS (2021) [JCR] [WOS]
POSTDOC
Sun, Cheng-Pu
RESEARCH ASSOCIATES
Chen, Bing-Mae